"Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer
- PMID: 37879768
- DOI: 10.1016/j.jtho.2023.08.001
"Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer
Comment in
-
In Response.J Thorac Oncol. 2023 Nov;18(11):e128-e129. doi: 10.1016/j.jtho.2023.08.025. J Thorac Oncol. 2023. PMID: 37879769 No abstract available.
Comment on
-
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.J Thorac Oncol. 2023 Nov;18(11):1550-1567. doi: 10.1016/j.jtho.2023.07.016. Epub 2023 Jul 18. J Thorac Oncol. 2023. PMID: 37473958
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
